Form 8-K - Current report:
SEC Accession No. 0001193125-24-023459
Filing Date
2024-02-05
Accepted
2024-02-05 07:31:01
Documents
17
Period of Report
2024-02-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d734141d8k.htm   iXBRL 8-K 25659
2 EX-99.1 d734141dex991.htm EX-99.1 28048
6 GRAPHIC g734141dsp010.jpg GRAPHIC 38121
7 GRAPHIC g734141g0205032634008.jpg GRAPHIC 2288
  Complete submission text file 0001193125-24-023459.txt   237545

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA plrx-20240204.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE plrx-20240204_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plrx-20240204_pre.xml EX-101.PRE 10813
18 EXTRACTED XBRL INSTANCE DOCUMENT d734141d8k_htm.xml XML 3518
Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 24593950
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)